Cartesian Therapeutics (RNAC) Receivables - Net (2015 - 2026)

Cartesian Therapeutics (RNAC) has reported Receivables - Net for 12 consecutive years, with $261000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables - Net fell 85.21% year-over-year to $261000.0; the TTM figure through Mar 2026 stood at $261000.0 (down 85.21% YoY), while the FY2025 annual figure was $1.1 million, up 27.87% from the prior year.
• Receivables - Net declined to $261000.0 in Q1 2026 per RNAC's latest filing, from $1.1 million in the prior quarter.
• Across five years, Receivables - Net topped out at $32.0 million in Q2 2024 and bottomed at $261000.0 in Q1 2026.
• Historically, Receivables - Net has averaged $6.6 million across 5 years, with a median of $4.9 million in 2023.
• Annual changes were most pronounced in 2024 — Receivables - Net jumped 494.97% — and 2025, when it tumbled 98.9%.
• Cartesian Therapeutics' Receivables - Net stood at $6.6 million in 2022, then fell by 11.01% to $5.9 million in 2023, then tumbled by 85.14% to $872000.0 in 2024, then increased by 27.87% to $1.1 million in 2025, then plunged by 76.59% to $261000.0 in 2026.
• Business Quant data shows RNAC's Receivables - Net at $261000.0 in Q1 2026, $1.1 million in Q4 2025, and $722000.0 in Q3 2025.